Pain management

Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research

Retrieved on: 
Wednesday, February 7, 2024
Managed Care, Research, Other Health, Pharmaceutical, Medical Devices, Infectious Diseases, Hospitals, Surgery, Clinical Trials, Science, Biotechnology, Health, Other Science, RX, Investigational New Drug, CRADA, Government, IND, Central nervous system, CNS, Trauma, Pain management, Post-traumatic stress disorder, Development, Pharmaceutical industry

The USAISR is the U.S. Department of Defense’s premier research organization for developing solutions for trauma and critical care challenges in combat casualties.

Key Points: 
  • The USAISR is the U.S. Department of Defense’s premier research organization for developing solutions for trauma and critical care challenges in combat casualties.
  • This study was designed to determine if Probudur reduces pain behaviors in a rat model of incisional pain.
  • “While the data from these studies will be further analyzed, these positive results are consistent with what we at Virpax have previously observed.
  • Probudur is being developed by Virpax to significantly reduce or eliminate the need for opioids after surgery or trauma in approved indications.

Nura Pain Clinics Announces Expansion with New and Improved Pain Pump Division Location - A First-of-Its-Kind in the US

Retrieved on: 
Tuesday, February 6, 2024
Environment, Patient, Pain, Chronic pain, Behavior, Nura, Medtronic, Pain management

EDINA, Minn., Feb. 6, 2024 /PRNewswire/ -- Nura Pain Clinics, Minnesota's foremost multidisciplinary pain management clinic, announced today that it has opened the doors to a new state-of-the-art facility to exclusively serve its chronic pain patients with implanted pain pumps.

Key Points: 
  • EDINA, Minn., Feb. 6, 2024 /PRNewswire/ -- Nura Pain Clinics , Minnesota's foremost multidisciplinary pain management clinic, announced today that it has opened the doors to a new state-of-the-art facility to exclusively serve its chronic pain patients with implanted pain pumps.
  • Located at 7390 France Avenue, the space allows Nura to deliver the highest standard of service and efficiency, specifically tailored to the unique needs of individuals seeking pain pump-related services.
  • This is a critical advantage for patients who otherwise may receive fragmented pain management by multiple providers at multiple locations.
  • For more information on Nura Pain Clinics and its focus on pain management, visit nuraclinics.com .

Branded Legacy, Inc. Innovates with Launch of the First 100% Clear Kava-Based Vaping Product on the Market

Retrieved on: 
Tuesday, February 6, 2024
Anxiety, Research, Migraine, Terpene, Therapy, Sleep, Pain, Safety, Headache, Cannabinoid, Alkaloid, Pain management, Health, Legacy, Teahouse

MELBOURNE, Fla., Feb. 6, 2024 /PRNewswire/ -- Branded Legacy, Inc. (OTC.PK: BLEG), a prominent Biotech company, proudly announces a major breakthrough in research and development efforts, leading the pack on new procedures for the extraction and refinement of kavalactones. In addition, The Alcannabist LLC, a wholly owned subsidiary of Branded Legacy , announced the official release of its new line of groundbreaking products designed to address diverse health and wellness needs.

Key Points: 
  • We were able to make a high purity extract that was completely translucent and very flavorful on the first day.
  • When we presented our extract to our kava suppliers, they asked to move forward immediately with a white label contract.
  • The Alcannabist's new products, which include: VapeRx Anti Anxiety, ElixRx Migraine/Headache Support, and Mood Mix Capsules, are now officially on the market.
  • The other three, ElixRx Plus Kava Anti Anxiety, ElixRx Plus Kava Sleep, and ElixRx Plus Kava Pain Management, will be included in their ElixRx line.

Zynex Receives FDA Clearance for its Next Generation NMES Device

Retrieved on: 
Tuesday, February 6, 2024
Rehabilitation, NMES, History, Exercise, Patient, FDA, Food, Pain management, Sale, Medical imaging

(NASDAQ: ZYXI ), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has received clearance from the U.S. Food and Drug Administration ("FDA") for the next generation M-Wave Neuromuscular Electrical Stimulation ("NMES") device.

Key Points: 
  • (NASDAQ: ZYXI ), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has received clearance from the U.S. Food and Drug Administration ("FDA") for the next generation M-Wave Neuromuscular Electrical Stimulation ("NMES") device.
  • NMES treatments have several uses, including aiding recovery from surgery, managing chronic conditions, and even enhancing exercise performance in healthy individuals.
  • The M-Wave replaces its predecessor, the E-Wave, which has been fundamental in NMES treatments across the U.S. since 1998.
  • "The M-Wave introduces the next evolution in NMES devices, allowing for more customizable treatments within clinical and home settings," said Thomas Sandgaard, CEO at Zynex Medical.

Danish dog owners are medicating their pets with unlicensed cannabis products – is it safe?

Retrieved on: 
Tuesday, February 6, 2024
Anxiety, Attention, Cannabis, Cannabidiol, Chronic pain, Travel, THC, Migraine, Research, Edible, Toxicity, Lethargy, Safety, Food, Dog, Oil, Cannabinoid, Osteoarthritis, Skin, Saliva, Thought, Pain management, Vomiting, Cat, Allergy, Health, Diarrhea, Pet, Medical imaging

Unsurprisingly, this trend has made its way to our pets, with a recent study suggesting that 38% of surveyed Danish dog owners routinely gave their pets some form of cannabis product.

Key Points: 
  • Unsurprisingly, this trend has made its way to our pets, with a recent study suggesting that 38% of surveyed Danish dog owners routinely gave their pets some form of cannabis product.
  • Previous studies suggest that 80% of dog owners in the US and Canada had bought cannabis products for their pet.
  • But, is CBD safe for our pets and could it be a useful addition to our pet’s healthcare regime?
  • Indeed, 36% of respondents in the Danish study indicated that they used cannabinoids for pain management in their pets.

Hikma announces US launch of COMBOGESIC® IV

Retrieved on: 
Monday, February 5, 2024
AFT, NSAID, Patient, Pain, Paracetamol, Pain management, Hikma Pharmaceuticals, Ibuprofen, Health, Hospital, Pharmaceutical industry

LONDON, Feb. 5, 2024 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the launch of COMBOGESIC® IV (acetaminophen and ibuprofen) injection in the US.

Key Points: 
  • LONDON, Feb. 5, 2024 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the launch of COMBOGESIC® IV (acetaminophen and ibuprofen) injection in the US.
  • COMBOGESIC® IV is an intravenous, opioid-free pain relief medicine that is a combination of 1,000 mg of acetaminophen and 300 mg of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID).
  • In 2021, Hikma signed an exclusive license and distribution agreement with AFT Pharmaceuticals (AFT) for the commercialization of COMBOGESIC® IV in the US.
  • Under the trade name of MAXIGESIC® IV outside of the United States, COMBOGESIC® IV is licensed in over 100 countries and marketed in over 20 countries.

Study Highlights Outcomes of New Jersey's 2017 Opioid Legislation

Retrieved on: 
Tuesday, January 30, 2024
Emergency department, FACEP, Opioid, Legislation, Cognitive behavioral therapy, Research, Prohibition, MD, Prescription, Government, Morristown Medical Center, Patient, Pain, Brandeis University, FACP, Emergency medicine, Partnership, Injury, MBA, Trauma, Communication, Pain management, Education, Associate, Advertising, Organization

Millburn, NJ, Jan. 30, 2024 (GLOBE NEWSWIRE) -- A recent study conducted at Morristown Medical Center, titled "New legislation in New Jersey reduced opioid use among trauma patients," provides an analysis of the effects of New Jersey's 2017 opioid legislation.

Key Points: 
  • Millburn, NJ, Jan. 30, 2024 (GLOBE NEWSWIRE) -- A recent study conducted at Morristown Medical Center, titled "New legislation in New Jersey reduced opioid use among trauma patients," provides an analysis of the effects of New Jersey's 2017 opioid legislation.
  • This change was based on evidence suggesting the potential for opioid dependency within a short period of initial use.
  • Findings from the Morristown Medical Center study indicate a correlation between the new law and a change in opioid prescription patterns.
  • "The findings from these studies provide insights into the impact of New Jersey's 2017 opioid legislation,” said Angelo Valente, Executive Director of PDFNJ.

ZYUS Strengthens Expertise of Clinical Advisory Committee with the Appointment of Dr. Hance Clarke

Retrieved on: 
Thursday, February 1, 2024
Science, Other Science, Research, Natural Resources, Pharmaceutical, Alternative Medicine, Health, Cannabis, Knowledge, School, Chronic pain, Hospital, Faculty, Patient, FRCPC, Public health, Toronto General Hospital, Advisory Committee, Knowledge translation, Medical school, Entrepreneurship, Queen Elizabeth, Consortium, Assistant, Pain management, Drug development, Risk, Anesthesiology, Toronto Centre, Doctor of Philosophy, University, Committee, Medicine, Pharmaceutical industry

ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, today announced the appointment of Hance Clarke, MD, PhD, FRCPC to ZYUS Life Sciences Inc.’s Clinical Advisory Committee.

Key Points: 
  • ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, today announced the appointment of Hance Clarke, MD, PhD, FRCPC to ZYUS Life Sciences Inc.’s Clinical Advisory Committee.
  • Dr. Clarke is internationally recognized for his outstanding contributions to research productivity and advancements in patient care.
  • "We are pleased to announce the appointment of Dr. Hance Clarke to the Clinical Advisory Committee," said Brent Zettl, President and CEO of the Company.
  • This strategic addition to our Clinical Advisory Committee reaffirms ZYUS’ commitment to advancing non-opioid-based therapies as a viable alternative for managing pain.”
    "I am honored to join ZYUS’ Clinical Advisory Committee and eager to contribute to ZYUS’ important work.

SHARx Names Veteran Clinician Dr. Tom Grissom, MD, First Medical Director

Retrieved on: 
Wednesday, January 31, 2024
Professional Services, Health, Hospitals, Practice Management, Insurance, Health Insurance, Pharmaceutical, University, Fellow, Syracuse University, Patient, Pain management, Nursing

SHARx, one of the nation’s fastest-growing patient advocacy companies, announced today that they have hired Dr. Tom Grissom, a 26-year clinical veteran as the company’s first Medical Director.

Key Points: 
  • SHARx, one of the nation’s fastest-growing patient advocacy companies, announced today that they have hired Dr. Tom Grissom, a 26-year clinical veteran as the company’s first Medical Director.
  • Dr. Grissom joins SHARx from the Algone Pain Intervention Clinic in Wasilla, AK, where he was a founder and CEO.
  • He will provide support to the SHARx clinical team, including its staff pharmacist.
  • “I am delighted to welcome Dr. Grissom to SHARx, where his clinical expertise and experience make him an asset to our most vulnerable members,” said SHARx CEO Corey Durbin.

Zynex Recognized in Top 25 Medical Device Companies for 2024

Retrieved on: 
Friday, February 2, 2024
Medical device, Sale, Zynex, Rehabilitation, Pain management

ENGLEWOOD, Colo., Feb. 2, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced The Healthcare Technology Report recognized Zynex as 9th amongst the Top 25 Medical Device Companies for 2024 .

Key Points: 
  • ENGLEWOOD, Colo., Feb. 2, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced The Healthcare Technology Report recognized Zynex as 9th amongst the Top 25 Medical Device Companies for 2024 .
  • "We're pleased to be included in the Top 25 Medical Device Companies for 2024," said Thomas Sandgaard, CEO of Zynex.
  • "The Healthcare Technology Report's rankings include some of the largest and most innovative companies in the medical device space.
  • We are proud to be included amongst our distinguished peers and believe these rankings are indicative of our outsized influence within the field.